Combined Human APOE and APP/PS1 Amyloid Models for Alzheimer’s Drug Development  

Taconic’s human APOE targeted replacement models are part of the original APOE knock-in model series developed by Nobuyo Maeda, Patrick Sullivan, and colleagues, in which the endogenous mouse Apoe coding sequence was replaced with human APOE alleles while retaining mouse regulatory control. AlzForum’s APOE3 Targeted Replacement model page describes these as the first APOE knock-in models and notes that they have been valuable for comparing the effects of the major ApoE isoforms.

The foundational APOE3/APOE4 publication using these models reported that apoE structure determines VLDL clearance and atherosclerosis risk in mice, which compared mice expressing human apoE4 or apoE3 in place of endogenous murine apoE. That study found that apoE4 and apoE3 replacement mice differed in VLDL composition and clearance, supporting the concept that apoE isoform structure alone can alter lipid handling and atherosclerosis-related phenotypes in vivo.

More recently, a Molecular Neurodegeneration publication directly compared humanized APOE mouse models from Taconic Biosciences, Cure Alzheimer’s Fund, and The Jackson Laboratory. The authors reported source- and genotype-dependent differences in apoE isoform levels, lipid profiles, and brain transcriptomic signatures, concluding that consistency and caution are important when selecting and using humanized APOE models.

For APOE3xARTE10 and APOE4xARTE10 studies, the practical implication is that using paired APOE3 and APOE4 models from the same Taconic APOE targeted replacement source can help support source-consistent genotype comparisons within a shared ARTE10 amyloid pathology framework.

APP/PS1 (ARTE10) provides the shared amyloid-beta pathology framework for APOE3xARTE10 and APOE4xARTE10. ARTE10 co-expresses human APP with the Swedish mutation and PSEN1 with the M146V mutation under the Thy1 promoter, leading to beta-amyloid plaque formation. The APOE3 and APOE4 crosses add defined human APOE allele context to this amyloid model, enabling researchers to evaluate APOE-dependent biology within a consistent disease-model background. 

ARTE10 is an APP/PS1 Alzheimer’s disease mouse model designed for amyloid-focused studies. It co-expresses human APP with the Swedish mutation and PSEN1 with the M146V mutation under the Thy1 promoter, leading to beta-amyloid plaque formation. In published characterization studies, ARTE10 mice develop progressive amyloid pathology with associated glial response, neuritic dystrophy, cerebral amyloid angiopathy, and amyloid signal detectable by Pittsburgh compound B imaging.

Commonly used Alzheimer’s disease mouse models differ in genetic design, pathology timeline, plaque distribution, neuroinflammatory features, cerebrovascular involvement, behavioral phenotypes, and suitability for specific study goals. ARTE10 provides a defined APP/PS1 amyloid framework that may be useful when researchers need progressive amyloid pathology, amyloid imaging compatibility, and a consistent background for evaluating amyloid-associated biology. Additional technical details are available on the APP/PS1 (ARTE10) model page.

For APOE3xARTE10 and APOE4xARTE10 studies, ARTE10 also provides a practical framework for incorporating human APOE context. Because ARTE10 and Taconic’s human APOE targeted replacement models are maintained on compatible C57BL/6-based backgrounds, the resulting APOE crosses support comparison of APOE3- and APOE4-associated biology while helping maintain genetic consistency across the paired model system.

ARTE10 is not intended to replace all Alzheimer’s disease models. Rather, it may be selected when researchers need a well-characterized amyloid pathology model for studies involving amyloid burden, amyloid imaging, glial response, cerebrovascular biology, or APOE-contextualized interpretation. Model selection should be guided by therapeutic mechanism, pathology timeline, required endpoints, and the biological context needed for the study.

Researchers may consider using both models when they want to compare therapeutic effects, pathology distribution, inflammatory response, or cerebrovascular features across common APOE3 reference and elevated-risk APOE4 contexts.

No. APOE3xARTE10 and APOE4xARTE10 have not been validated to predict clinical amyloid-related imaging abnormalities, or ARIA. However, ARIA has become an important consideration in the clinical use of amyloid beta–directed antibody therapies, and FDA-approved prescribing information for these therapies highlights ARIA risk, higher ARIA incidence in ApoE ε4 homozygotes, and the use of ApoE ε4 testing and MRI monitoring to inform clinical risk management.

These models are intended to support mechanistic investigation of APOE-dependent amyloid pathology, neuroinflammation, and cerebrovascular biology within a controlled Alzheimer’s disease model framework. They may be useful for studying biology relevant to cerebrovascular and safety-related questions, but ARIA prediction would require dedicated validation data.

Yes. APOE3xARTE10, APOE4xARTE10, and eligible individual APOE models may be bred or cross-bred within a Taconic Colony Management Solutions (CMS) project, including with custom or customer-supplied models. For eligible Taconic models, license fees may be waived when the breeding or cross-breeding work is performed at Taconic within CMS. This waiver applies only to breeding activities conducted within Taconic CMS and does not provide unrestricted rights to breed purchased models outside of Taconic-managed projects.

Yes. APOE3xARTE10 and APOE4xARTE10 can support workflows in which animals are shipped directly to contract research organization partners for in vivo pharmacology, pathology, imaging, behavioral, or biomarker studies. These models are also available for direct purchase by contract research organizations.